Lila Levinson, PhD,  Science Writer—

Filgotinib, Alfasigma’s candidate oral therapy for adults with active axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS), eased symptoms and showed a favorable safety profile in a Phase 3 clinical trial. The trial, called OLINGUITO (NCT05785611), comprised two parallel studies: one involving patients with radiographic axSpA (r-axSpA),…

Higher levels of physical activity are linked to better disease outcomes and quality of life in people with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS), according to a recent study. “Patients with axSpA should be especially encouraged to exercise, as it is particularly beneficial for disease-related outcomes,” researchers wrote.